Could cause temporary or reversible harm; serious harm is unlikely.
Presence of particulate matter
| Brand name | OMNIPAQUE |
| Generic name | IOHEXOL |
| Active ingredient(s) | IOHEXOL |
| Distributed by / for | GE Healthcare Inc., Marlborough, MA 01752 USA |
| NDC | 0407-1413-63 |
| Full product label | GE Healthcare Omnipaque (iohexol) Injection, 300 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc., Marlborough, MA 01752 USA, NDC 0407-1413-63. |
| Recalling firm | GE Healthcare Ireland Limited |
| Distribution | U.S. Nationwide. |
| Quantity | 866,570 vials |
| Recall initiated | 2026-03-24 |
| Report date | 2026-04-15 |
| Recall completed | — |
| Recall number | D-0447-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Carrigtwohill Ireland |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗